Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

AtaiBeckley Inc. (ATAI)

$5.36 -5.47% NASDAQ: ATAI · 15-min delayed
  • NEW YORK, New York
  • Public · NASDAQ: ATAI
  • 99 employees
$1.5BMarket cap
$4.1MRevenue · FY2025
-$660.0MNet income
99Employees
ATAINASDAQ
2021IPO

About AtaiBeckley Inc.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$4.1M
Net income
-$660.0M
Total assets
$292.7M
Market cap
$1.5B
Operating margin
-33341.2%
Net margin
-48717.2%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2024

Financial statements

Income statement

Revenue
$308.0K
Operating expenses
$103.0M
Operating income
-$102.7M
Income tax
-$356.0K
Net income
-$150.0M
EPS (basic)
$-0.93
EPS (diluted)
$-0.93

Balance sheet

Total assets
$159.4M
Current assets
$80.1M
Total liabilities
$42.8M
Current liabilities
$25.0M
Shareholders’ equity
$116.6M

Cash flow

Operating cash flow
-$82.4M
Investing cash flow
$59.2M
Financing cash flow
$5.4M
Net cash flow
-$17.9M

Statements via Polygon.io (SEC filings)

NASDAQ: ATAI
$5.36 -5.47%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$2.02 $6.45

52-week range

Market cap
$1.5B
EPS (diluted)
$-0.93
Shares outstanding
271.3M
Open
Day range
Prev close
Volume
IPO date
Jun 18, 2021

AtaiBeckley Inc. (ATAI) Stock Price

  • Reported a net loss of $660.0M in FY2025.
  • Revenue declined 98% from FY2021 to FY2024.
  • Trading 17% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review AtaiBeckley Inc..

Write a review
Newsroom

News about AtaiBeckley Inc.

News & sentiment via Polygon.io

FAQ

AtaiBeckley Inc.: frequently asked questions

Is AtaiBeckley Inc. an American company?

AtaiBeckley Inc. is a US-based company headquartered in New York, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is AtaiBeckley Inc. headquartered?

AtaiBeckley Inc. is headquartered in New York, New York, United States.

Is AtaiBeckley Inc. publicly traded?

Yes — AtaiBeckley Inc. is a publicly traded company. Its stock trades under the ticker symbol ATAI on the NASDAQ.

What does AtaiBeckley Inc. do?

AtaiBeckley Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →